24/7 Market News Snapshot 25 November, 2024 – Cognition Therapeutics, Inc. Common Stock (NASDAQ:CGTX)

November 25, 2024

DENVER, Colo., 25 November, 2024 (247marketnews.com) – (NASDAQ:CGTX) are discussed in this article.
Cognition Therapeutics, Inc. (CGTX) is currently garnering attention in the financial markets, with pre-market trading reflecting a remarkable surge of over 53% to reach $0.655, compared to the previous close of $0.428. This increased trading activity has been accompanied by a significant volume of 10.26 million shares, indicating heightened investor interest and potential optimism around the company’s recent announcements.

The excitement surrounding CGTX is largely fueled by groundbreaking results from its Phase 2 SHINE study, which examined the efficacy of CT1812 as a novel treatment for Alzheimer’s disease. The study’s findings revealed a remarkable 95% reduction in cognitive decline among patients treated with CT1812 who exhibited lower plasma levels of the biomarker p-tau217. This substantial improvement not only demonstrates the potential of CT1812 in preserving cognitive functions but also correlates with enhancements in critical biological indicators related to Alzheimer’s.

Participants receiving CT1812 exhibited a notable 2.7-point improvement on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) over a six-month duration, compared to those on a placebo. Furthermore, the treatment was associated with normalization of significant blood-based biomarkers, including reductions in GFAP, a neuroinflammatory marker, and NfL, indicative of neurodegeneration.

Dr. Anthony O. Caggiano, the Chief Medical Officer at Cognition, articulated the positive implications of these results, emphasizing CT1812’s potential as a disease-modifying treatment that not only slows cognitive decline but also enhances brain cell functionality. The company intends to share detailed findings at scientific conferences throughout 2025 and engage with regulatory bodies to refine the design of its Phase 3 clinical program. Cognition Therapeutics is committed to addressing the challenges posed by neurodegenerative conditions, marking a hopeful advancement in the fight against Alzheimer’s disease.

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.